Magle Chemoswed Holding Ab Net Assets
Magle Chemoswed Holding Ab net assets. Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has net assets worth Skr395.84 Million SEK (≈ $42.60 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr911.03 Million ≈ $98.04 Million USD) and total liabilities (Skr515.19 Million ≈ $55.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Magle Chemoswed Holding Ab annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr395.84 Million |
| % of Total Assets | 43.45% |
| Annual Growth Rate | 31.99% |
| 5-Year Change | 185.21% |
| 10-Year Change | N/A |
| Growth Volatility | 87.71 |
Net Assets of Magle Chemoswed Holding Ab (2017–2025)
Net assets of Magle Chemoswed Holding Ab from 2017 to 2025. This chart illustrates how Magle Chemoswed Holding Ab's net assets have evolved over time, based on quarterly financial data. See Magle Chemoswed Holding Ab (MAGLE) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Magle Chemoswed Holding Ab (2017–2025)
The table below shows the annual net assets of Magle Chemoswed Holding Ab from 2017 to 2025. For live market cap and overall valuation, see MAGLE market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr395.84 Million ≈ $42.60 Million |
-29.39% |
| 2024-12-31 | Skr560.60 Million ≈ $60.33 Million |
+254.31% |
| 2023-12-31 | Skr158.22 Million ≈ $17.03 Million |
+7.81% |
| 2022-12-31 | Skr146.77 Million ≈ $15.79 Million |
+5.75% |
| 2021-12-31 | Skr138.79 Million ≈ $14.94 Million |
+19.52% |
| 2020-12-31 | Skr116.12 Million ≈ $12.50 Million |
+2.17% |
| 2019-12-31 | Skr113.66 Million ≈ $12.23 Million |
+124.30% |
| 2018-12-31 | Skr50.67 Million ≈ $5.45 Million |
+17.89% |
| 2017-12-31 | Skr42.98 Million ≈ $4.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Magle Chemoswed Holding Ab's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Magle Chemoswed Holding Ab Net Assets Breakdown (December 2025)
Magle Chemoswed Holding Ab net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.03 Million | 0.26% |
| Other Components | Skr394.81 Million | 99.74% |
| Total Equity | Skr395.84 Million | 100.00% |
Magle Chemoswed Holding Ab Competitors by Market Cap
The table below lists competitors of Magle Chemoswed Holding Ab ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KlickOwn AG
STU:ILK1
|
$384.73K |
|
Chelverton UK Dividend Trust PLC
LSE:SDV
|
$385.14K |
|
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
|
$386.39K |
|
Nexera Technologies Ltd.
NASDAQ:NEXR
|
$387.08K |
|
Blencowe Resources Plc
LSE:BRES
|
$383.58K |
|
Canyon Creek Food Company Ltd
V:CYF
|
$381.39K |
|
Troubadour Resources Inc
V:TR
|
$380.15K |
|
Arecor Therapeutics PLC
LSE:AREC
|
$379.00K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Magle Chemoswed Holding Ab's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 560,603,000 to 395,844,000, a change of -164,759,000 (-29.4%).
- Net loss of 159,885,000 reduced equity.
- Other comprehensive income increased equity by 4,103,000.
- Other factors decreased equity by 8,977,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-159.88 Million | -40.39% |
| Other Comprehensive Income | Skr4.10 Million | +1.04% |
| Other Changes | Skr-8.98 Million | -2.27% |
| Total Change | Skr- | -29.39% |
Book Value vs Market Value Analysis
This analysis compares Magle Chemoswed Holding Ab's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr8.45 | Skr0.17 | x |
| 2018-12-31 | Skr4.98 | Skr0.17 | x |
| 2019-12-31 | Skr11.18 | Skr0.17 | x |
| 2020-12-31 | Skr15.24 | Skr0.17 | x |
| 2021-12-31 | Skr12.85 | Skr0.17 | x |
| 2022-12-31 | Skr13.59 | Skr0.17 | x |
| 2023-12-31 | Skr14.69 | Skr0.17 | x |
| 2024-12-31 | Skr27.33 | Skr0.17 | x |
| 2025-12-31 | Skr19.17 | Skr0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Magle Chemoswed Holding Ab utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -56.51%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 2.30x
- Recent ROE (-40.39%) is below the historical average (-1.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 11.74% | 4.48% | 0.76x | 3.44x | Skr747.80K |
| 2018 | -6.43% | -3.08% | 0.69x | 3.01x | Skr-8.33 Million |
| 2019 | 0.66% | 0.59% | 0.60x | 1.87x | Skr-10.62 Million |
| 2020 | 1.57% | 1.28% | 0.72x | 1.71x | Skr-9.79 Million |
| 2021 | 3.08% | 3.24% | 0.56x | 1.71x | Skr-9.60 Million |
| 2022 | 6.23% | 6.28% | 0.58x | 1.72x | Skr-5.53 Million |
| 2023 | 7.69% | 7.14% | 0.62x | 1.73x | Skr-3.65 Million |
| 2024 | 2.13% | 5.06% | 0.22x | 1.95x | Skr-44.12 Million |
| 2025 | -40.39% | -56.51% | 0.31x | 2.30x | Skr-199.47 Million |
Industry Comparison
This section compares Magle Chemoswed Holding Ab's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,426,563
- Average return on equity (ROE) among peers: -118.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Magle Chemoswed Holding Ab (MAGLE) | Skr395.84 Million | 11.74% | 1.30x | $384.44K |
| 2cureX AB (2CUREX) | $58.86 Million | -12.44% | 0.07x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $7.35 Million |
| AcouSort AB (ACOU) | $78.63K | -354.63% | 2.32x | $7.49 Million |
| Active Biotech AB (ACTI) | $55.60 Million | -67.09% | 0.26x | $11.63 Million |
| Alzinova AB (ALZ) | $123.82 Million | -16.60% | 0.08x | $7.32 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $76.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $13.71 Million | -366.46% | 0.39x | $4.83 Million |
| Alligator Bioscience AB (ATORX) | $468.31 Million | -32.04% | 0.09x | $1.10 Million |
| BioInvent International AB (BINV) | $885.82 Million | -48.47% | 0.12x | $26.95 Million |
| BioArctic AB (publ) (BIOA-B) | $60.76 Million | 94.77% | 10.65x | $2.49 Billion |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more